Brandon G. Smaglo

Oncology

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer.

Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer.

Journal: Cancers

Published: May 05, 2026

Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer.

Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer.

Journal: The oncologist

Published: July 24, 2025

Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates.

Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates.

Journal: Nature communications

Published: June 08, 2025

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Journal: Nature medicine

Published: May 16, 2025

KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients.

KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients.

Journal: medRxiv : the preprint server for health sciences

Published: March 17, 2025

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma.

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma.

Journal: Journal of hematology & oncology

Published: February 19, 2025

Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series.

Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series.

Journal: Cancers

Published: August 19, 2024

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 05, 2024

Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.

Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.

Journal: The oncologist

Published: April 23, 2024

Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.

Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.

Journal: Annals of surgery

Published: March 20, 2024

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Journal: Cell

Published: February 17, 2024

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.

Journal: The Lancet. Oncology

Published: September 19, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026